Showing 121–132 of 192 resultsSorted by latest
Pharma & Biotech
In the second quarter, Stryker (SYK) saw strong procedural volumes, driven by solid fundamentals and increased use of robotic-assisted surgery.
In the latest quarter, Abbott’s nutrition sales grew by 7.5%, fueled by strong performance in international adult nutrition and U.S. paediatric nutrition.
LLY is investing heavily in treating diseases, with 11 new molecules in clinical trials across various indications and several late – stage Phase 3 programs.
AbbVie also started the Phase 3 CERVINO trial to test ABBV-383 monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have had at least two previous treatments.
Thermo Fisher expanded its clinical trial supply services by opening a new ultra-cold facility in Bleiswijk, Netherlands, to provide tailored support for high-value therapies like cell and gene therapies, biologics etc
Merck & Co Inc (MRK) Equity Report Q2FY24
MRK is focused on strategic business development to enhance its pipeline.
BSX also shared positive results from the ongoing MODULAR ATP clinical trial for the Modular CRM (mCRM ) System, which met all safety and effectiveness endpoints.
On July 2, 2024, Biogen (BIIB) acquired HI-Bio, a biotech company focused on treatments for severe immune diseases.
In Q2, NVS advanced its pipeline by completing FDA submissions for Scemblix in first-line CML and atrasentan in IgAN, and updating data for Kisqali in early breast cancer.
In May 2023, TEVA launched its “Pivot to Growth” strategy with four main goals: boosting key products, advancing innovation, strengthening its generics business, and optimizing operations.
Regeneron (REGN) is approaching 1mn patients using DUPIXENT worldwide.
Zoetis continues to advance animal care globally. Since its last earnings report, ZTS has received several new approvals.